Literature DB >> 12404667

Onset of action of antidepressants: results of different analyses.

Chris Thompson1.   

Abstract

Because the value of antidepressants is hampered by their delay in onset of action, considerable attention has been focused on developing a drug that acts more rapidly. However, although specific studies are now ongoing, there have been no peer-reviewed prospective onset of action trials published in the literature to date. Some data are currently available from post-hoc pooled analyses and numerous methods have been developed for evaluating the onset of action; these include the time to response, the time to onset of therapeutic effect, pattern analysis and survival analyses. Such an analysis of four large-scale, double-blind studies has provided evidence for an earlier onset of action with mirtazapine than with the SSRIs (fluoxetine, paroxetine and citalopram). Significant differences were seen between mirtazapine and the SSRIs after 1 week of treatment. This effect was consistent across the four different methodologies and appears to be due to a specific antidepressant effect rather than an early effect on, for example, sleep. These findings await confirmation from specifically designed prospective onset of action studies. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12404667     DOI: 10.1002/hup.386

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  19 in total

1.  Recognizing and Treating the Physical Symptoms of Depression in Primary Care.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004

2.  The future of antidepressant pharmacotherapy.

Authors:  David Baldwin; Chris Thompson
Journal:  World Psychiatry       Date:  2003-02       Impact factor: 49.548

3.  Pharmacokinetics of fluoxetine in rhesus macaques following multiple routes of administration.

Authors:  E K Sawyer; L L Howell
Journal:  Pharmacology       Date:  2011-07-14       Impact factor: 2.547

4.  Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease.

Authors:  Maryka Quik; Archana Mallela; Jason Ly; Danhui Zhang
Journal:  Mov Disord       Date:  2013-07-08       Impact factor: 10.338

Review 5.  The role of dopamine agonists in the treatment of depression in patients with Parkinson's disease: a systematic review.

Authors:  Albert F G Leentjens
Journal:  Drugs       Date:  2011-02-12       Impact factor: 9.546

6.  Long-term Ameliorative Effects of the Antidepressant Fluoxetine Exposure on Cognitive Deficits in 3 × TgAD Mice.

Authors:  Li Jin; Li-Feng Gao; Dong-Sheng Sun; Hao Wu; Qun Wang; Dan Ke; Hao Lei; Jian-Zhi Wang; Gong-Ping Liu
Journal:  Mol Neurobiol       Date:  2016-06-21       Impact factor: 5.590

7.  Alpha2-adrenoceptor blockade accelerates the neurogenic, neurotrophic, and behavioral effects of chronic antidepressant treatment.

Authors:  Sudhirkumar U Yanpallewar; Kimberly Fernandes; Swananda V Marathe; Krishna C Vadodaria; Dhanisha Jhaveri; Karen Rommelfanger; Uma Ladiwala; Shanker Jha; Verena Muthig; Lutz Hein; Perry Bartlett; David Weinshenker; Vidita A Vaidya
Journal:  J Neurosci       Date:  2010-01-20       Impact factor: 6.167

Review 8.  Trends in the development of new antidepressants. Is there a light at the end of the tunnel?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Med Chem       Date:  2004-04       Impact factor: 4.530

9.  Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease.

Authors:  Marwa Aboukhatwa; Laura Dosanjh; Yuan Luo
Journal:  Mol Neurodegener       Date:  2010-03-12       Impact factor: 14.195

10.  Targeting phosphocreatine metabolism in relapsing-remitting multiple sclerosis: evaluation with brain MRI, 1H and 31P MRS, and clinical and cognitive testing.

Authors:  Melissa Cambron; Tatjana Reynders; Jan Debruyne; Harmen Reyngoudt; Annemie Ribbens; Erik Achten; Guy Laureys
Journal:  J Neurol       Date:  2018-09-05       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.